Gene Therapy is fastest growing segment fueling the growth of Ornithine Transcarbamylase (OTC) Deficiency Treatment Market

 

OTC deficiency is a urea cycle disorder which results in excessive levels of ammonia in the blood (hyperammonemia). This condition leads to poor muscle control, vomiting, seizures etc. Gene therapy, drugs and supplements are used to treat OTC deficiency.

The global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market is estimated to be valued at US$ 1,116.1 Million in 2023 and is expected to exhibit a CAGR of 6.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
Gene therapy is emerging as a promising treatment option for OTC deficiency. It aims at introducing a corrected copy of the OTC gene to produce functional enzyme and reduce ammonia levels. AAV-based gene therapy approach has shown encouraging clinical responses in phase 1/2 studies. Increased R&D and promising clinical trial results are propelling the growth of gene therapy segment in the OTC deficiency treatment market. Other key trends include strategic collaborations between industry players and research institutes to develop novel therapeutics. Rising public awareness about urea disorders and availability of treatment options are also fueling market growth.

Segment Analysis

The global OTC deficiency treatment market is segmented based on treatment, route of administration and distribution channel. On the basis of treatment, the market is segmented into nitrogen scavengers, riboflavin, and diet control. The nitrogen scavengers segment is expected to dominate the market during the forecast period due to the presence of approved drugs such as Buphenyl and Ravicti that are actively used for the treatment of OTC deficiency.

Key Takeaways

The global OTC deficiency treatment market is expected to witness high growth, exhibiting CAGR of 6.2% over the forecast period, due to increasing prevalence of genetic disorders. The global market size for OTC deficiency treatment was valued at US$ 1,116.1 Mn in 2023.

Regional analysis

North America is expected to dominate the global OTC deficiency treatment market over the forecast period. This is attributed to factors such increasing healthcare spending and presence of key pharmaceutical players in the region. Asia Pacific is anticipated to exhibit fastest growth during the forecast period due to rising healthcare infrastructure and disposable income in developing countries such as India and China.

Key players

Key players operating in the OTC deficiency treatment market are Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, GSK plc., GC Biopharma, Bayer AG, Bharat Biotech, Serum Institute of India Pvt. Ltd., Sartorius AG, Johnson & Johnson Services, Inc., and Bio Farma. These players are focusing on new drug development and product launches to strengthen their market position.

Comments

Post a Comment

Popular posts from this blog

Unveiling Health Secrets: Exploring the Potential of Blood-Based Biomarkers

Image
  The human body is a complex and intricate system, often harboring subtle signs of its inner workings. One of the most promising avenues for unlocking these secrets lies within our bloodstream – a treasure trove of information encoded in the form of blood-based biomarkers. These biomarkers, measurable indicators present in the blood, hold the potential to revolutionize healthcare by providing early detection, accurate diagnosis, and personalized treatment approaches. Blood-based biomarkers encompass a wide range of molecules – from proteins and nucleic acids to metabolites and even circulating cells. Researchers have been diligently working to identify specific biomarkers associated with various diseases and conditions. For instance, elevated levels of certain proteins might point to cardiovascular diseases, while specific genetic material could indicate the presence of cancer. By analyzing these biomarkers, clinicians gain valuable insights into an individual's health status, en...
Read more

Revolutionizing Biology: Advancements in Single Cell Analysis Techniques

Image
  Single cell analysis has emerged as a groundbreaking technology that is revolutionizing the field of biology. Traditionally, biological studies were conducted on populations of cells, averaging out the heterogeneity present within them. However, the advent of single cell analysis has enabled scientists to delve into the complexity of individual cells, uncovering a wealth of previously inaccessible information. Advancements in single cell analysis techniques have paved the way for a deeper understanding of cellular heterogeneity, gene expression, and cellular behavior. One of the most remarkable techniques is single-cell RNA sequencing (scRNA-seq), which allows scientists to measure gene expression in individual cells. This breakthrough has led to the identification of rare cell types, understanding of cellular communication networks, and the discovery of novel biomarkers. Moreover, single cell imaging techniques, such as single cell fluorescence microscopy, have enabled research...
Read more

Medical Robots Market Poised to Grow Owing to Improving Healthcare Infrastructure

Image
 The Medical Robots Market is anticipated to witness robust growth due to rising healthcare spending across the globe. Medical robots are used to perform minimal invasive surgeries with greater accuracy and flexibility. Growing preference for Robot-Assisted Surgery (RAS) over conventional open surgeries due to benefits such as shorter recovery time and minimum operative scars has been augmenting demand for medical robots. Key functions include guiding and positioning surgical accessories like guide tubes in radiology and guiding catheter and wires in cardiology. With rising chronic disease prevalence associated with aging populations, the need for more surgical procedures is surging which requires precise action minimally invasive robotic systems can provide. The Global Medical Robots Market is estimated to be valued at US$ 11.47 Bn in 2024 and is expected to exhibit a CAGR of 16% over the forecast period 2023 to 2030. Key Takeaways: Key players operating in the Medical Robo...
Read more